TEMAZEPAM IMPURITY, OXAZEPAM- |
OXOZEPAM |
OXAZEPAM CIV |
SERAX |
WY-3498 |
J3.308A |
SERENID FTE |
ZAXOPAM |
OXAZEPAM |
LEDERPAM |
NSC-169448 |
TAZEPAM |
(+-)-OXAZEPAM |
(RS)-OXAZEPAM |
SERAX® |
chembl:CHEMBL568 |
rxcui:7781 |
chemidplus:604-75-1 |
pubchem.compound:4616 |
drugbank:00842 |
FDA Approval | 1965 |
Drug Class | small molecule |
Drug Indications | Hypnotics and Sedatives |
Year of Approval | 1965 |
Drug Class | hypnotics and sedatives |
potentiator |
Trial Name | - |
Novel drug target | Established target |
potentiator |
Trial Name | - |
Novel drug target | Established target |
potentiator |
Trial Name | - |
Novel drug target | Established target |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Novel drug target | Established target |
Trial Name | - |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
positive modulator (activating) |
potentiator |
Novel drug target | Established target |
Trial Name | - |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Novel drug target | Established target |
Trial Name | - |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
ligand |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Novel drug target | Established target |
Trial Name | - |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Novel drug target | Established target |
Trial Name | - |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
OXAZEPAM | Primary Drug Name |
Drug Class | hypnotics and sedatives |
Year of Approval | 1965 |
Drug Indications | Hypnotics and Sedatives |
Drug Class | small molecule |
FDA Approval | 1965 |
CHEMBL568 | ChEMBL Drug ID |
D09LDR | TTD Drug ID |